Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Takeda, Daiichi Sankyo, Astellas Lead Drug Firms' Corporate Image Ranking
December 20, 2010
- Kyorin Turns Down Sawai's Merger Proposal Again
December 20, 2010
- Otsuka: Aquaretic Agent Samsca for Volume Overload
December 20, 2010
- NPhA Reconfirms Opposition to Point Services
December 20, 2010
- PMDA's Reform Team Proposes Unification of PAFSC's PAC and Committees on Drugs
December 20, 2010
- C. Viehbacher Appointed as New PhRMA Chairman
December 20, 2010
- Sales of Ethical Drugs Down 3.4% in October: Crecon Report
December 20, 2010
- FPMAJ to Draft GL on Supply of Information on Drugs Used Off-Label
December 20, 2010
- New Drugs Make Up For Lipitor Patent Expiration: President Umeda of Pfizer
December 20, 2010
- Daiichi Sankyo Prioritizes 1st-in-Class Drugs in R&D: President Nakayama
December 20, 2010
- AZ's Ticagrelor Obtains EC Approval to Prevent Atherothrombotic Events in ACS
December 20, 2010
- Rifaximin to Drive ASKA's Business: President Yamaguchi
December 20, 2010
- BMS Applies for Additional Indication for SPRYCEL in Japan
December 20, 2010
- Sprycel Obtains EC Approval for a New Indication
December 20, 2010
- Novartis Recommends Rasilez for Use in First-Line Therapy
December 20, 2010
- Gov't Aims to Create Japanese Version of NIH
December 20, 2010
- FDA Advisory Committee Recommends Approval of Contrave for Obesity: Takeda
December 20, 2010
- MCHC Aims at Operating Profits of \120 Bil. for Healthcare Business in FY2015
December 20, 2010
- NCGM to Start IIT to Compare 3 Antidiabetic Drugs
December 20, 2010
- Pfizer to Develop Orphan Drugs Even if Profits Are Small: Mr Matsumori
December 20, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…